Thu, November 3, 2022
Wed, November 2, 2022
Tue, November 1, 2022

Andreas Argyrides Maintained (UBX) at Buy with Increased Target to $36 on, Nov 2nd, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-increased-target-to-36-on-nov-2nd-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Andreas Argyrides of Wedbush, Maintained "Unity Biotechnology, Inc." (UBX) at Buy with Increased Target from $4 to $36 on, Nov 2nd, 2022.

Andreas has made no other calls on UBX in the last 4 months.



There are 2 other peers that have a rating on UBX. Out of the 2 peers that are also analyzing UBX, 0 agree with Andreas's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Andreas


  • Salim Syed of "Mizuho" Maintained at Strong Buy with Increased Target to $80 on, Tuesday, August 16th, 2022
  • Yigal Nochomovitz of "Citigroup" Maintained at Strong Buy with Increased Target to $80 on, Monday, August 15th, 2022

Publication Contributing Sources